RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Drug trial results refine treatment during angioplasty operations

Aug 31, 2010 - 4:00:00 AM
The low dose regimen did not reduce the risk of major or minor bleeding or vascular access complications compared to standard dose regimen. The low dose regimen did not lower the risk of major bleeding but did lower minor bleeding by 60 per cent. There was a trend, however, for higher risk of death, myocardial infarction or target vessel revascularization with low dose vs. standard dose UFH. The rates of catheter thrombosis were very low (0.5 per cent and 0.1 per cent in the low and standard dose UFH groups). In the standard dose arm, only about one in five patients required an additional UFH bolus to reach target ACT.

 
[RxPG] A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

In a prior study, the OASIS 5 trial, researchers from McMaster University showed that a blood thinner fondaparinux compared to another blood thinner, enoxaparin, reduced serious bleeding and prevented deaths in patients with heart attacks. A limitation of this new agent, fondaparinux, was its higher rates of clot formation in equipment during angioplasty. As a result, an additional blood thinner UFH had been recommended during angioplasty to prevent clotting in those who had received fondaparinux, but there was uncertainty about the optimal dose.

Even though UFH has been used during angioplasty since the procedure was first performed, little is known about the optimal dose of the agent.

An international group of researchers from 18 countries found patients undergoing angioplasty did not benefit from a lower dose of UFH compared to a standard dose in those on fondaparinux.

Importantly, the addition of either low or standard dose UFH to fondaparinux did not increase serious bleeding and prevented clot formation in equipment during angioplasty when compared to patients treated with fondaparinux alone in OASIS 5. As a result, adding standard dose UFH to fondaparinux maintains the major advantage of fondaparinux (lower bleeding) while preventing clotting during the angioplasty procedure.

Our data clearly shows that adding UFH to fondaparinux maintains a low rate of major bleeding and prevents catheter thrombosis, said interventional cardiologist Dr. Sanjit Jolly, an assistant professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University.

Dr. Jolly is scheduled to present the results of the FUTURA-OASIS 8 (Fondaparinux with UnfracTionated heparin dUring Revascularisation in Acute coronary syndromes) trial at the annual European Society of Cardiology Congress in Stockholm, Sweden on August 31. The study was also published simultaneously in the Journal of the American Medical Association (JAMA).

FUTURA-OASIS 8 is a Phase III, multicentre, multinational, randomized, parallel-group trial of 2,026 patients undergoing angioplasty within 72 hours of arriving in a hospital with unstable angina or a heart attack. As soon as possible after their arrival, patients were enrolled and received fondaparinux 2.5 mg daily. Patients who required angioplasty were then randomized to low fixed dose heparin or standard dose heparin with activated clotting time (ACT) guidance during angioplasty. The low fixed dose UFH regimen consisted of a dose of 50 U/kg irrespective of use of GP IIb/IIIa inhibitors (another group of drugs used to prevent clots at time of angioplasty). The standard dose UFH regimen consisted of a dose of 85 U/kg or 60 U/kg when GP IIb/IIIa inhibitor used, adjusted by blinded ACT.

The low dose regimen did not reduce the risk of major or minor bleeding or vascular access complications compared to standard dose regimen. The low dose regimen did not lower the risk of major bleeding but did lower minor bleeding by 60 per cent. There was a trend, however, for higher risk of death, myocardial infarction or target vessel revascularization with low dose vs. standard dose UFH. The rates of catheter thrombosis were very low (0.5 per cent and 0.1 per cent in the low and standard dose UFH groups). In the standard dose arm, only about one in five patients required an additional UFH bolus to reach target ACT.






Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)